Clinical Trial Search

Primary: Part I: Objective Response Rate (ORR) of Single-agent Cediranib in Participants With Advanced Alveolar Soft Part Sarcoma (ASPS) — 0; 0; 0; 1 Participants

Primary: Percentage of Evaluable Participants Achieving Progression-Free Survival (PFS) at 3 Months — 81.8 percentage of participants

Primary: Minimal Response Rate in Pediatric Participants With Alveolar Soft Part Sarcoma (ASPS) — 0 Participants

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: Tumor Best Response Rate — 0 Participants

Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events

Primary: Progression-free Survival (PFS) (Cohort 1 Only) — 5.0597 months

Primary: Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response — 0 participants

Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: The Primary Endpoint for This Trial Was the Percent of Confirmed Tumor Responses. Confirmed Tumor Response to Treatment Was Defined as a Complete or Partial Response(Per…

Primary: Response Rate for Amrubicin in Patients With Metastatic or Advanced Sarcoma as First Line Therapy. — 13 percentage of pt with a partial response

Primary: Progression-Free Survival (PFS) — 4.04; 2.96 Months

Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years

Primary: Progression-free Survival (PFS) — 7.0; 20.0 weeks — p=<0.001

Primary: Disease Control Rate, Defined as the Number of Patients Who Achieved Complete Response, Partial Response or Stable Disease For a Period of More Than 4 Months. — 0…

Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months

Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient

Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…

Primary: Pharmacokinetics (PK): Area Under The Concentration Curve Zero to Infinity (AUC[0-∞]) Doxorubicin — 2580; 2570; 2400; 2470 nanogram*hour/milliliter (ng*h/mL)

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 1; 1; 0; 1 Participants

Primary: Clinical Benefit Rate — 22 Participants

Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants

Primary: Progression Free Survival at Week 12 — 0; 0; 0; 0 participants — p=0.653

Primary: Percentage of Patients With Progression-free Survival at 16 Weeks. — 36.4 Percentage of patients

Primary: Cohorts 1, 3, 4, 5, 6 and 7: Objective Response Rate (ORR) — 9.4; 9.4; 0.0; 16.1 Percentage of participants

Primary: Percentage of Participants Who Experienced Event-Free Survival (EFS) Events as Per Independent Review Committee (IRC) Assessment — 52.5; 68.9 percentage of participants

Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants

Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)

Primary: Number of Adverse Events in Participants — 6; 64 Participants